Danish Merck collaboration is ahead of schedule

The Denmark-based biotech company, Nordic Bioscience, has completed enrollment of patients for a major phase II study conducted on behalf of German pharma giant Merck ahead of schedule – which makes the company hope for more.

stopur tid

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles